Bioscience

Venaxis expands European distribution network for APPY1 appendicitis test

Venaxis expands European distribution network for APPY1 appendicitis test

CASTLE ROCK - Venaxis Inc . (Nasdaq: APPY), an in vitro diagnostic company focused on gaining FDA approval and commercialization of its APPY1 appendicitis test, announced it has signed... Read More

By: Steve Tuesday March 19, 2013 0 comments Tags: APPY1, Castle Rock, Don Hurd, EMELCA Bioscience, Venaxis

University of Colorado licenses dental polymer technology to 3M

University of Colorado licenses dental polymer technology to 3M

BOULDER - An advanced polymer technology developed at the University of Colorado-Boulder has been licensed to 3M. The licensed technology, developed by a team of researchers led by CU-Boulder... Read More

By: Steve Monday March 18, 2013 0 comments Tags: 3M, Boulder, Christopher Bowman, MaryBeth Velequette

Omni Bio announces favorable results in its lead recombinant molecule

Omni Bio announces favorable results in its lead recombinant molecule

DENVER - Omni Bio Pharmaceutical Inc. (OTCBB: OMBP), a pharmaceutical company focused on commercializing new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical... Read More

By: Steve Monday March 18, 2013 0 comments Tags: AAT, Bruce Schneider, Denver, Fc-AAT

CU Cancer Center testing new drug to treat mouth sores from cancer radiation treatment

CU Cancer Center testing new drug to treat mouth sores from cancer radiation treatment

AURORA - The University of Colorado Cancer Center said it is testing a promising new drug to treat and protect against mouth sores commonly associated with cancer treatment. A CU Cancer... Read More

By: Steve Monday March 18, 2013 0 comments Tags: Aurora, Smad 7, Xiao-Jing Wang

N30 Pharmaceuticals treats first patient with investigational cystic fibrosis drug

N30 Pharmaceuticals treats first patient with investigational cystic fibrosis drug

BOULDER - N30 Pharmaceuticals Inc. announced it has administered the first dose in its Phase 1b/2a clinical trial of N6022 in patients with cystic fibrosis. The study is a multi-center,... Read More

By: Steve Friday March 15, 2013 0 comments Tags: Boulder, Charles Scoggin, cystic fibrosis, N30 Pharmaceuticals, N6022

Sundance Diagnostics to target risk of suicide, violence in genetic test development

Sundance Diagnostics to target risk of suicide, violence in genetic test development

BOULDER - Sundance Diagnostics Inc ., a diagnostics development company, will focus on risk of suicide and the potential risk of acts of violence in development of its genetic tests designed to... Read More

By: Steve Thursday March 14, 2013 1 comments Tags: Boulder, genetic tests, Kim Bechthold, Sundance Diagnostics

CU-Denver's certificate in Bioinnovation and Entrepreneurship opening doors for students

CU-Denver's certificate in Bioinnovation and Entrepreneurship opening doors for students

AURORA - Carsten Schnatwinkel already had a doctorate in molecular cell biology but is discovering career avenues he hadn't considered through a certificate program in Bioinnovation and... Read More

By: Steve Monday March 11, 2013 0 comments Tags: Arlen Meyers, Aurora, David Forlani